In February 2019, the board appointed Torreya, a global investment bank specialising in life sciences, asNeuren’s corporate advisor to evaluate all potential corporate transactions, for individual products, defined territories, or Neuren’s entire business.
A formal process commenced in April and is presentlyunderway, engaging with third parties in the US, Europe and Japan.
Ann: Neuren advances pipeline for neurodevelopmental disorders, page-2
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$12.84 |
Change
-0.260(1.98%) |
Mkt cap ! $1.597B | |||
| Open | High | Low | Value | Volume |
| $13.20 | $13.36 | $12.82 | $2.862M | 218.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 203 | $12.84 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.85 | 234 | 10 |
View Market Depth
| Last trade - 13.47pm 16/06/2025 (20 minute delay) ? |
| NEU (ASX) Chart |